Three Bridge Wealth Advisors LLC Buys Shares of 22,371 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Three Bridge Wealth Advisors LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 22,371 shares of the company’s stock, valued at approximately $120,000.

A number of other institutional investors also recently modified their holdings of CRVS. Cubist Systematic Strategies LLC bought a new position in Corvus Pharmaceuticals in the second quarter valued at about $44,000. Nwam LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Corvus Pharmaceuticals during the 4th quarter valued at approximately $73,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals during the 3rd quarter worth approximately $74,000. Finally, Virtu Financial LLC bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $83,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Finally, Oppenheimer lifted their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Stock Up 1.6 %

Shares of Corvus Pharmaceuticals stock opened at $5.04 on Thursday. The stock has a market cap of $323.87 million, a price-to-earnings ratio of -5.42 and a beta of 1.07. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $10.00. The company’s fifty day moving average is $5.74 and its 200 day moving average is $5.96.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.